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Systemic treatment of mice with the nucleoside analog 9-(2-hydroxyethoxy-
methyl)guanine (acycloguanosine [aciclovir]) was found to be highly effective
against acute type 1 herpes simplex virus infection of the pinna. The drug ablated
clinical signs and reduced virus replication both in tissue local to the inoculation
site and within the nervous system. Provided that moderate-sized virus inocula
were used, acycloguanosine treatment reduced or prevented the establishment of
a latent infection in the dorsal root ganglia relating to the sensory nerve supply
of the ear. However, although it aborted artificially produced infections in dorsal
root ganglia, acycloguanosine was found not to be effective against the latent
infection once established. This finding strongly indicated that latent herpes
simplex virus in mice can exist in a nonreplicating form.
Mice, inoculated subcutaneously in the pinna
with a suitable strain of herpes simplex virus
(HSV), undergo an infection which closely re-
sembles the human disease (7) and forms a
convenient model for the study of antiviral
chemotherapeutic agents. Concentrations of in-
fectious virus in the ear may be followed by
testing tissue homogenates, and the results of
these titrations are found to give reproducible
patterns of virus growth declining to undetect-
able levels in survivors 8 to 10 days after inoc-
ulation. Local inflammatory changes produced
by the virus can be gauged by measuring ear
thickness. Progression of virus into the nervous
system evokes neurological signs; the most ob-
vious of these is the development of flaccid
paralysis of the inoculated pinna, which fails to
respond to mild external stimuli (7). Subse-
quently latent virus may be reactivated by ex-
planting and culturing the three cervical ganglia
that relate to the sensory nerve supply of the
pinna.
The nucleoside analog 9-(2-hydroxyethoxy-
methyl)guanine (acycloguanosine [aciclovir])
has been reported to be an effective and ex-
tremely selective agent against several herpes
viruses both in vitro and in a number of animal
models (2, 13). However, previously published
reports of acycloguanosine in vivo have not ex-
amined the effect of the drug on the establish-
ment and maintenance of a latent infection with
HSV. In our study we have examined in detail
the effect of the agent on virus replication in
vivo during both the acute and the subsequent
latent phase of the infection. To provide addi-
tional information on the effects of the drug on
infected cells in the nervous system, some ex-
periments were carried out on mice infected by
intraneural inoculation.
MATERLALS AND METHODS
Mice. Three-week-old BALB/c female mice were
obtained from Bantin and Kingman (Grimston, Ald-
brough, Hull, England) and used when they were 4
weeks old.
Virus strains. The principal virus used was HSV-
1 (SC-16), a clone of the type 1 strain of herpes simplex
virus, isolated by S. K. R. Clarke (Public Health
Laboratory, Bristol, England) from an oral lesion (7).
The strain of pseudorabies virus (N,A-2) was origi-
nally obtained from J. B. McFerran, Veterinary Re-
search Division, The Farm, Stormont, Belfast, N. Ire-
land, and shown to be highly virulent for mice (4).
The thymidine kinase-deficient mutant used in this
study was Cl(101)TK- (6). This is a mutant of HSV-1,
originally isolated by Dubbs and Kit (1) and called by
them B2006.
Cell line. BHK-21 cells were grown in Eagle me-
dium supplemented with 10% (vol/vol) tryptose phos-
phate broth and 10% calf serum (ETC medium) (14).
For reactivation experiments the proportion of calf
serum was reduced to 2%.
Preparation and adnistration of the drugs.
The compounds were received as dry powders from
Wellcome Research Laboratories, Research Triangle
Park, N.C. They were suspended in distilled water at
3.2 or 1.6 mg/ml; the suspension was briefly sonically
disrupted before use and administered either subcu-
taneously (s.c.) or intraperitoneally (i.p.) in twice-daily
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injections to give a total dose of 25, 50 or 100 mg/kg
per day. Preliminary work had indicated that a daily
dose of 50 mg of acycloguanosine per kg per day
produced a marked effect on the clinical signs in HSV-
infected mice. In earlier experiments the compounds
were given s.c. into the scruff of the neck, but this was
found inconvenient when handling large numbers of
mice. Later, compounds were given i.p.; comparisons
of the effectiveness of the two routes of administration
showed no differences between the s.c. and the i.p.
routes. No specific tests were carried out on the tox-
icity of acycloguanosine for mice. However, no abnor-
mal signs were observed during 1 month of continuous
daily treatment with 100 mg/kg per day i.p., the high-
est dose employed in these studies.
Inoculation of the mice and virus growth in
mouse ear. A 20-pl volume of virus suspension was
inoculated intradermally into the left pinnae of an-
aesthetized 4-week-old mice (7). To study the repli-
cation of virus in ears, the left pinnae were cut off
from groups of mice, and the tissue from each mouse
was then minced with scissors and ground in 1 ml of
ETC in a small glass grinder. The suspensions were
then diluted for independent assay using BHK cells
(12).
Measurement of ear thickness. Ear thickness
was measured with a Mitutoyo engineer's micrometer
screw gauge. The thickness was measured at a point
on the anterior edge, 5 mm from the root of the ear.
The estimate has proved to be a rapid and reproduc-
ible indication of the severity of infection. It has ena-
bled repeated estimates, presumably of the inflam-
matory processes, on the same set of animals and has
been valuable in following the course of acute disease
in the presence or absence of different treatments.
The normal 4-week-old mouse ear is 220Mm thick, and
thickness increases to 400 to 500 Llm by 5 days after
infection. The increased thickness has been expressed
in micrometers as the difference in thickness between
the infected and uninfected ears of individual mice.
Reactivation of latent virus from dorsal root
ganglia. The second, third, and fourth cervical dorsal
root ganglia were dissected from mice into 0.5 ml of
ETC with serum reduced to 2%. The ganglia were
maintained in this medium in closed bottles at 37°C
for 5 or 6 days. The tissue was then homogenized and
titrated for the presence of infectious virus as de-
scribed above.
Intraneural inoculation. Mice were anesthetized,
and the sciatic nerve was exposed by blunt dissection
of the thigh muscles at a point 1 cm from the root of
the tail. Approximately 1 M1 of virus suspension was
then injected into the sciatic nerve using a finely
drawn pipette. The inoculum was later calibrated by
expressing the same volume of a similar virus suspen-
sion into medium and titrating the number of plaque-
forming units (PFU) present.
RESULTS
Effects of acycloguanosine on primary
infection in the pinna. Mice were inoculated
with 10' or 105 PFU of virus and divided into
four groups treated with the following com-
pounds: (i) acycloguanosine; (ii) 2,6-diaminopu-
rine; (iii) 2,6-diaminopurine arabinoside, approx-
imately equal in effect to 9-fl-D-arabinofurano-
syladenine in animal models (3), and (iv) un-
treated. In each case the drug was administered
s.c. in twice-daily doses (at 9 a.m. and 6 p.m.)
commencing the day before virus inoculation
and continuing for 10 days thereafter. The larger
inoculum produced a more severe disease in
untreated mice with overt signs of neurological
involvement. The lower inoculum of 104 PFU
per mouse usually produced a nonlethal disease
and thus resembled more closely the natural
human infection. Acycloguanosine ameliorated
the course of the disease, as judged by clinical
signs and the titers of infectious virus obtained
from ear homogenates on day 3 after inoculation,
which was the expected peak of virus multipli-
cation (Table 1, columns I, II, and III). Only
samples from the acycloguanosine-treated mice
showed a striking reduction in virus titer from
the untreated controls. For comparison, the drug
was given in similar doses to mice inoculated
with 104 PFU of the herpes virus pseudorabies
(which was found to be nonsusceptible to the
drug in vitro) into the pinna, but it had no effect
on the course of the disease in this case, and all
the mice died.
The effectiveness of acycloguanosine was fol-
lowed throughout the period of the acute disease
by taking samples of ear tissue from mice on
successive days (Fig. la). The development of
ear thickness in the same mice is shown in Fig.
lb; twice-daily treatment was continued
throughout the experiment. The measurement
of ear thickness was also used to examine the
effects ofcommencing or terminating drug treat-
ment during the acute phase (Fig. 2). After an
input of 104 PFU, treatment begun 3 days after
infection prevented further marked increase in
ear thickness (Fig. 2a). When treatment (started
before inoculation) was terminated 2 days after
virus inoculation, this short period of adminis-
tration still produced a considerably ameliorat-
ing effect. Similar results were obtained using
the larger inoculum of 105 PFU (Fig. 2b). The
rapid ameliorating effects of acycloguanosine
suggested that there might be nonspecific effects
on inflammation; similar effects of reduced ear
thickness, however, could not be demonstrated
in acycloguanosine-treated mice in which ears
were inflamed by injection of endotoxin, heat-
killed HSV-1 (SC-16), or the thymidine kinase-
deficient mutant Cl(101)TK-, or by topical
treatment with the contact-sensitizing agent ox-
azalone. From these tests it was concluded that
the effects of the drug described above resulted
principally from reduced virus multiplication.
It was noted (as shown in Fig. la) that infec-
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TABLE 1. Clinical signs and virus isolation from pinnae and cervical dorsal ganglia ofmice after
inoculation with HSV-1 (SC-16)
Virus ~~~~~~~~~~III ITreatmenta Vdor8uVse II Virus titer Virus MiceTreatinent'se I Ear on day 3 p.i. detected sihown(dose) (PFU Mortalityb paral 1o31ndayl 3PFU in to be
permouse)
~~~~per ear ± SD)Y ganglia latentlyon day 3d infected'
None iO5 4/13 9/9 5.5 ± 0.3 2/2 7/7
2,6-Diaminopurine 10W 3/10 7/7 5.5 ± 0.4 3/3 7/7
(25 mg/kg per day)
2,6-Diaminopurine 10" 0/10 8/10 4.7 ± 0.7 (P > 0.1)' 2/2 9/9
arabinoside
(50/mg/kg per day)
Acycloguanosine 105 0/10 2/10 3.5 ± 0.8 (P < 0.005) 4/4 6/10
(50 mg/kg per day)
None i04 1/15 14/14 4.6 ± 0.2 NDf 7/8
2,6-Diaminopurine 104 0/15 14/14 4.6 ± 0.2 ND 8/9
(25 mg/kg per day)
Acycloguanosine 104 0/15 0/15 1.7 ± 0.6 (P < 0.001) ND 7/9
(50 mg/kg per day)
a Drugs were administered in twice-daily s.c. injections from day before inoculation until 10 days thereafter.b Ratio of number of mice dying or showing ear paralysis to total number in the group or number surviving.
'Geometric mean titers of separate samples obtained from five mice for each treatment. p.i., postinfection;
SD, standard deviation.
d Ratio of number of mice from which virus was isolated to total number tested.
'Student's t test applied to difference in geometric mean between treated group and untreated controls.
fND, Not determined.
tious virus was not completely eliminated from
the ears of treated mice and indeed showed a
rise 4 to 6 days after inoculation, also reflected
in the ear thickness curves (Fig. lb). This late
rise was found to be reproducible; similar curves
were obtained in two repeats of this late stage of
the acute infection. Three explanations have
been considered. The first was the possibility
that drug-resistant mutants had emerged during
the course of acute infection in the presence of
acycloguanosine. This was tested by dividing the
ear homogenates from treated and untreated
mice and assaying for infectivity in the absence
or presence of 10 ,uM acycloguanosine. This con-
centration is approximately 10 50% inhibitory
doses in plaque reduction assays using HSV-1
(SC-16) in BHK-21 cells; it has little activity on
the thymidine-kinase deficient mutant
Cl(101)TK-. The results (Table 2) showed no
evidence of the emergence of resistant strains of
virus.
The second possibility was that the suspen-
sion of acycloguanosine used for treating the
mice was gradually deteriorating during storage.
Comparisons ofthe efficiency ofstored and fresh
suspensions showed no evidence of deterioration
either in plaque-reduction assays or when tested
in vivo. This could not have accounted for the
secondary rise in virus activity in the later stages
of the acute infection.
The third possibility is that the virus interacts
with a population of cells which are less suscep-
tible to the drug. This is discussed later.
Effects of acycloguanosine on the estab-
lishment of neurological infection. After
replication in the epidermal tissue of the pinna,
virus progresses probably by axonal flow (5, 8)
to the sensory ganglia supplying the ear, in par-
ticular the second, third, and fourth cervical
ganglia. In the experiment in which 10' PFU was
inoculated the drug was seen to prevent the
appearance of clinical signs of neurological in-
volvement (Table 1, columns I and II). Never-
theless, virus was detected qualitatively in gan-
glia removed from these mice on day 3 (Table 1,
column IV) in both treated and untreated mice.
Acycloguanosine treatment was continued until
day 10 after inoculation, and then, 2 weeks later,
the second, third, and fourth cervical ganglia
were tested qualitatively for the presence of
latent virus. The results of these isolations are
shown in Table 1 (column V). The remaining
mice inoculated with 104 PFU were also checked
for the presence of latent virus by quantitative
assay 6 days after explanation; the animals were
sampled 7 weeks and 10 weeks after inoculation.
These results and those of another experiment
in which the drug was given i.p. are shown in
Table 3. There was evidence for reduction in the
establishment of latency in these three experi-
ments, particularly marked in the last.
The observation that latent infection could be
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FIG. 1. (a) Infectious virus monitored in the ears
ofmice after inoculation with 104 PFUofHSV-1 (SC-
16) into the left ear. (0) Untreated; (0) acycloguano-
sine, 50 mg/kg per day i.p., from the day before
inoculation. Points represent geometric mean titers
with ranges obtained from three mice at each time.
(b) Development of ear thickness in mice inoculated
with IO' PFU ofHSV-1 (SC-16) into the left ear. Ear
difference is the thickness of left ear minus that of
right ear, in micrometers. (0) Untreated; (0) acyclo-
guanosine, 50 mg/kgper day i.p., from the day before
inoculation.
established despite continuous treatment during
the acute phase of the infection suggested that
acycloguanosine is not effective against the la-
tent virus. To further this investigation, mice in
which a latent infection was already established
(mice surviving an inoculum of 105 PFU into the
ear 1 to 6 months previously) were treated with
acycloguanosine with a number of different reg-
imens. These included s.c. for i.p. administration
given continuously for 1 month (50 mg/kg per
day), or in some cases short discontinuous treat-
ments of 50 or 100 mg/kg per day were em-
ployed. Mice were then killed, and their cervical
dorsal root ganglia were assessed for latency by
the in vitro test. Some mice were sampled during
a course of treatment, others at various times
after treatment was completed. None of these
experiments showed any significant reduction in
the number of animals harboring the latent vi-
rus, or in the titers of virus obtained from the
ganglia of such mice (Table 4). The wide varia-
-1 0 1 2 3 4 5 6 7 8 9
Time After Inoculation (Days)
300
E 200
a
0
JcD
I
4
-1 0 1 2 3 4 5 6 7
Tine After Inoculation (Days)
8 9
FIG. 2. Development of ear thickness in mice in-
oculated with HSV-1 (SC-16) and treated -with acyclo-
guanosine, commencing or terminating treatment at
various times. (0) Untreated or treatment ceased;
(0) acycloguanosine, 50 mg/kg per day i.p., or treat-
ment commenced. (a) Virus inoculum was 104 PFU
per mouse. ( I) Treatment commenced 1 day before
inoculation; a IV treatment commenced 3 days after
inoculation (T III) treatment ceased 2 days after in-
oculation. (b) Virus inoculum was 10' PFUper mouse.
1I) Treatment commenced I day before inoculation;
aI1) treatment commenced 4 days after inoculation;
(T III) treatment ceased 4 days after inoculation.
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TABLE 2. Development of acycloguanosine resistance"
Virus titer (log,o PFU per ear)
TreatInent Asayedb Mouse on day p.i.'
no.
4 5 6 7
Acycloguanosine A 1 <0.0 2.1 <0.0 <0.0
(50 mg/kg per day)' 2 1.3 2.2 0.8 <0.0
3 0.3 2.3 0.8 <0.0
B 1 <0.0 <0.0 <0.0 <0.0
2 <0.0 0.6 <0.0 <0.0
3 <0.0 <0.0 <0.0 <0.0
Untreated A 1 3.4 2.4 3.0 2.7
2 3.8 2.9 3.0 <0.0
3 4.3 2.1 2.5 <0.0
B 1 <0.0 <0.0 <0.0 <0.0
2 <0.0 1.6 <0.0 <0.0
3 <0.0 0.0 <0.0 <0.0
a Titers of virus in ears of individual mice obtained during treatment after inoculation of 104 PFU of HSV-1
(SC-16) into the pinna.
b A, Assayed in absence of drug; B, assayed in presence of 10 50% inhibitory doses of acycloguanosine.
e p.i. Postinoculation.
d Twice-daily doses i.p. commencing the day before virus inoculation and continued throughout the experi-
ment.
TABLE 3. Levels of infection in homogenates of
cervical dorsal root ganglia after explantation and
incubation in vitro"
Expt. I: virus titer" Expt. II: virus titer'
Untreated S.c.-treated Untreated I.p.-treated
mice mice' mice mice"
>4.5 >4.5 5.0 <0.0
>4.5 >4.5 4.8 <0.0
>4.5 3.5 4.3 <0.0
>4.5 2.9 4.3 <0.0
>4.5 1.5 3.8 <0.0
>4.5 1.0 0.0
>4.5 0.8 <0.0
<0.0 <0.0
<0.0
a Mice were inoculated with 104 PFU of HSV-1 (SC-
16) into the pinna several weeks previously.
bLogio virus in second, third, and fourth cervical
ganglia, combined for individual mice, after 6 days of
incubation. Experiment I, cf. Table 1.
'Mice were treated s.c. or i.p. with 50 mg of acyclo-
guanosine per kg per day from the day before to 10
days after inoculation.
tion in titers observed in explants from both
treated and untreated groups is to be expected,
because once the virus reactivates in the culture
there is a rapid multiplication of infectious virus.
The experiments show, however, that there was
no marked reduction of the latent infection as
judged by the in vitro reactivation test.
Effect of acycloguanosine on infection by
intraneural inoculation. The experiments de-
scribed above had not proved that acycloguano-
sine is effective within the peripheral nervous
system. Although reduced neurological involve-
ment was observed in the primary infection, this
might have been explained by the effects of the
drug on local virus replication in the skin, reduc-
ing the supply of virus into the nervous system.
Experiments were therefore carried out in which
virus was injected intraneurally. By inoculation
directly into sciatic nerve it was hoped to pro-
duce a neurological infection that did not require
prior virus replication in non-neurological tissue.
The results of these experiments, in which treat-
ment was commenced either the day before virus
inoculation or 3 h after inoculation (Table 5),
showed that acycloguanosine was highly effec-
tive in reducing both clinical signs and levels of
infectious virus in several neurological tissues:
sciatic nerve, spinal cord, and the first sacral and
IV, V, and VI lumbar dorsal root ganglia. It was
concluded, from the marked reductionis in virus
titer observed in these tissues from drug-treated
mice, that adequate levels of the drug were
available within these tissues, and in particular
within the dorsal root ganglia, to affect virus-
infected cells within the peripheral nervous sys-
tem. Eight intraneural-infected, drug-treated
mice were also tested for latency by subsequent
explantation of the lumbar-sacral ganglia, and
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TABLE 4. Latent infection experiments'
Time after Acycloguanosine-treated mice Untreated mice
Expt. Treatment treatment Cultures Culturesregimen before yielding vir yielding Logio
explantation yim virus"bvrsvirus virus
1 1 month, 50 mg/kg per 3 weeks 8/10 -5.0, 25.0, 25.0, 25.0, 19/20 -5.0, 25.0, 25.0, 25.0,
day s.c. 2.7, 2.7, 2.3,1.0 25.0, 25.0, -5.0,
25.0, 25.0, -5.0,
2-5.0, 2:5.0, 2-5.0,
25.0, 25.0, 5.0, 4.9,
4.8, 4.6
2 1 month, 50 mg/kg per 3 weeks 5/6 5.4, 5.2, 4.1, 4.0, 0.8 7/12 5.0,4.8,4.6,3.3,2.7, 1.7,
day s.c. 1.7
3 5 days, 50 mg/kg per 1 day 5/5 4.7, 3.3, 2.9, 0.0, 0.0 5/5 5.2, 5.0, 4.8, 1.6, 1.4
day i.p. 3 days 5/5 5.5, 4.9, 3.0, 2.0, 1.5 4/4 5.8, 5.7, 5.7, 5.6
11 days 4/4 5.5,4.5, 3.6, 1.3 4/4 5.5, 4.5, 3.6, 1.3
4 1 month, 50 mg/kg per 1 week 7/7 5.1,5.0,4.8,4.7,3.5,2.7, 7/7 5.7,5.4,5.3,4.9,4.6,4.0,
day i.p. 1.4 1.4
5 1 week, 50 mg/kg per Explanted 6/8 5.6, 5.3, 5.2, 4.6, 4.1, 2.7 2/10 4.0, 1.3
day i.p. during
treatment
Totals 40/45 3.7 ± 1.7d 48/62 4.4 ± 1.3d
(89%) (77%)
a Five experiments in which mice with established latent HSV infection were treated with acycloguanosine and their cervical
dorsal root ganglia were then explanted and issessed for the presence of the latent infection. Treatment of groups of mice
commenced 1 to 6 months after inoculation with 10' PFU of HSV-1 ($C-16). They had recovered from the acute disease and
now carried the infection in latent form. Acycloguanosine was administered daily with the dose and treatment period shown.
b Ratio of number of explant cultures (CII, CIII, and CIV combined for each mouse) yielding virus/number of mice tested.
Log,o virus in the virus-yielding explants after 5 to 6 days of incubatio.
d Geometric mean titer ± standard deviation.
all were shown to be harboring latent virus.
Thus, these experiments were similar to the ear
model in that treatment had not prevented the
establishment of a latent infection in spinal gan-
glia.
DISCUSSION
The important observations made in this
study of acycloguanosine in mice infected with
HSV were as follows. (i) Continuous treatment
with the drug had a marked effect on the clinical
signs produced in infected animals. Inflamma-
tion was reduced as judged by ear thickness even
when treatments were of brief duration, al-
though it did not reduce similar inflammation
induced by other agents. (ii) Although clinical
signs were reduced, low levels of virus replication
persisted for several days. (iii) Treatment that
commenced before inoculation and was contin-
ued throughout the acute disease reduced, but
did not always prevent, the establishment of a
latent infection. (jv) Treatment appeared to
have no effect on the latent infection once estab-
lished. (v) Acycloguanosine was effective against
active infection in the nervous system after in-
traneural injection of virus, but again did not
prevent the establishment of latency.
The persistence of virus in the ear and the
nature of the late peak of virus activity observed
on day 5 was not elucidated, but it could not be
attributed to the development of resistance to
acycloguanosine. Of various possible mutations
to drug resistance, mutants lacking thymidine
kinase have been studied, and two of these,
obtained artificially have been found by
us to show extremely low virulence in the mouse
model (6). Perhaps a more likely explanation is
that there are scattered cells in which the virus
replicates in the ear but which are less suscep-
tible to the action of the drug either because of
reduced permeability, because of differences in
their thymidylate metabolism, or because the
virus in them is not undergoing the lytic repli-
cation cycle.
The observation that latency was established
despite treatment would be consistent with and
probably reflects the reduction of virus titers
observed in the ear during week 1 of the infec-
tion. We believe that latency can be established
(though less reproducibly) with comparatively
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TABLE 5. Effect of acycloguanosine treatment on virus titers in neural tissues'
Log,o PFU in individual mice at
day postinoculation:
Treatment 1 3 6
Ah B A B C A B
Untreated 5.8 5.3 2.0
5.7 5.4 4.3
5.6 4.1 3.0
5.5 3.9 3.3
4.9 4.4 5.2
3.7 2.1 1.3
1.6 <0.0 <0.0
Acycloguanosine' 0.3 1.0 0.6
0.0 <0.0 <0.0
<0.0 <0.0 <0.0
<0.0 <0.0 <0.0
<0.0 0.0 <0.0
Untreated 3.5 2.4 5.3 4.2
2.9 2.3 5.2 4.9 Mice dead
1.8 1.8 3.8 3.4
Acycloguanosined 2.3 1.3 1.9 0.0 <0.0 <0.0
2.2 1.4 <0.0 <0.0 <0.0 <0.0
<0.0 <0.0 <0.0 0.7 <0.0 <0.0
a Mice received 5 x 105 PFU of HSV-1 (SC-16) in the left sciatic nerve.
b A, Left lumbar sacral dorsal root ganglia; B, left sciatic nerve, 1-cm length, from close to spinal cord; C,
lumbar sacral spinal cord, 1-cm length.
eAcycloguanosine, 100 mg/kg per day i. p. in twice-daily injections, beginning 1 day before virus inoculation
and continuing for 10 days
d Acycloguanosine, 100 mg/kg per day i. p. in twice-daily injections, beginning 3 h after virus inoculation and
continuing for 10 days
small inocula, e.g., 102 or 103 PFU (unpublished
data). This would explain why the drug had
little effect on the establishment of latency after
the inoculation of 105 PFU and a variable effect
using the smaller dose of virus. Our results sug-
gest, however, that prompt treatment of the
primary infection would minimize the likelihood
of establishment of latency, and that, if latency
is not completely prevented, could reduce the
number of latently infected foci in the ganglia.
It was of great interest to investigate the po-
tential of acycloguanosine treatment of mice in
which the latent infection was already estab-
lished. This failure to cure latently infected mice
is consistent with the static model for latency. It
is possible that recurrence of disease in humans
or in animal models is preceded by active virus
replication in ganglion cells (9). In this situation,
some latently infected cells may become suscep-
tible to the activity of the drug, and it is inter-
esting to speculate that after several such recur-
rences the reservoir of latently infected cells
might be destroyed. Work is now in progress to
test these possibilities in the mouse ear model.
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